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Background: Cardiovascular diseases (CVD) pose a burden on healthcare systems. There is 
evidence that pharmacist-led medication review with follow-up (MRF) improves therapeutic goal 
achievement in CVD risk factors, such as hypertension, type 2 diabetes mellitus and dyslipidaemia. 
Objectives:  To evaluate the economic impact of MRF added to Chilean primary care in CVD risk 
factors, by assessing the cost-effectiveness in older adults. 
Methodology: A systematic review was conducted to evaluate the economic evaluations of 
pharmacist-led MRF in outpatients with CVD risk factors. Recommendations were generated to 
design a cluster randomised controlled trial (cRCT). 
A cRCT was conducted in public primary care centres (clusters) in Chile to study the effect of 
MRF added to usual care compared to usual care alone. Older adults with five or more 
prescriptions, moderate or high CVD risk and enrolled in a primary care CVD prevention program 
were included. The intervention had three components: Pharmacists’ training, MRF, and a practice 
change facilitator. Patients were followed-up for a year. For the economic analysis, health-related 
quality of life (HRQoL) was measured and was used to estimate quality-adjusted life-years 
(QALYs). Costs were evaluated form the public third-party payer perspective and were measured 
as 2019 United States dollars (USD). A cost-effectiveness threshold of 16,207 USD was used. 
A trial-based cost-utility analysis was performed. Costs and QALYs were estimated through a 
multilevel model that accounted for clustering and covariates, while missing data was addressed 
using multiple imputation. Uncertainty was evaluated through a non-parametric bootstraping. As a 
second analysis, a state-transition microsimulation model was developed to extrapolate outcomes 
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to a lifetime time horizon. Patient-level data was used to derive the model’s probabilities. 
Deterministic and probabilistic sensitivity analyses were performed.  
Results: Eleven studies were included in the systematic review. Eight found the intervention to be 
cost effective, while two found it to be dominant. Both, the trial-based and model analyses deemed 
the intervention as cost-effective. Incremental cost-effectiveness ratios of $434/QALY and 
$751/QALY respectively, were found. The trial-based analysis found increased dominant iterations 
when patients with more than nine medications were evaluated. In the model, a difference between 
groups of 5.9% in CVD mortality was observed. Sensitivity analyses showed either cost-
effectiveness or dominance. 
Conclusion: International evidence shows that MRF was value for money in outpatient settings. 
An adapted MRF method was deemed as a cost-effective addition to primary care in Chile with 
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This thesis is presented in fulfilment of the doctoral degree (Doctor of Philosophy) requirements 
of the Graduate School of Health, University of Technology Sydney, Australia.  
This document was structured as a thesis by compilation. Chapter 1 presents a synopsis describing 
the general approach of this thesis and research. Chapter 2 provides the background for 
cardiovascular diseases’ clinical and economic impact, particularly in Chile. Medication review 
with follow-up is proposed as a clinically effective strategy to address cardiovascular risk factors. 
Chapter 3 introduces the basic concepts of economic evaluations in healthcare and contains a 
published systematic review of pharmacist-led medication review conducted in outpatients with 
cardiovascular risk factors such as, hypertension, type 2 diabetes mellitus and dyslipidaemia. This 
study frames the current state of cost-effectiveness analyses in the area, and a quality assessment 
to provided recommendations for future research. Chapter 4 describes the methods of the Polaris 
trial, a cluster randomised controlled study that included older adults with cardiovascular risk 
factors in Chilean primary care. This trial was a collaboration between UTS, the Pontifical Catholic 
University of Chile, and the Chilean government. A description of the Polaris method of MRF is 
presented. Chapter 5 and 6 contain submitted papers of a trial-based cost-effectiveness analysis and 
a decision-analytic model, using the Polaris trial results. Chapter 7 discuss the research outputs, 
explores limitations of each study, addresses transferability to other settings and proposes future 
directions. Chapter 8 presents conclusions arising from this research. 
Antonio Osvaldo Ahumada Canale is the primary author of the publications. Co-authors 
contributed to the conception or design of the work, data collection, data analysis and 
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ADR: adverse drug reactions 
CAD: Canadian dollar 
CI: confidence interval 
CKD: chronic kidney disease 
cRCT: cluster randomised control trial 
CVD: cardiovascular diseases 
DBP: diastolic blood pressure 
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GP: general practitioner 
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LMICs: Low and middle-income countries 
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MTM: medication therapy management 
NCDs: non-communicable diseases 
OR: odds ratio 
PAHO: Pan American Health Association 
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PI: prediction interval 
PUC: Pontificia Universidad Católica de Chile 
PW: Pharmacotherapy workup 
QALYs: quality-adjusted life-years 
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RCT: randomised controlled trial 
RN: registered nurse 
SBP: systolic blood pressure 
T2DM: type 2 diabetes mellitus 
TC: total cholesterol 
TG: triglycerides 
TIDieR: template for intervention description and replication 
UTS: University of Technology Sydney 
USD: United States dollars 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
